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ABSTRACT
OBJECTIVES This study sought to describe the health status of outpatients with heart failure and reduced ejection
fraction (HFrEF) by sex, race/ethnicity, and socioeconomic status (SES).
BACKGROUND Although a primary goal in treating patients with HFrEF is to optimize health status, whether disparities
by sex, race/ethnicity, and SES exist is unknown.
METHODS In the CHAMP-HF (Change the Management of Patients with Heart Failure) registry, the associations among
sex, race, and SES and health status, as measured by the Kansas City Cardiomyopathy Questionnaire-overall summary
(KCCQ-os) score (range 0 to 100; higher scores indicate better health status) was compared among 3,494 patients from
140 U.S. clinics. SES was categorized by total household income. Hierarchical multivariate linear regression estimated
differences in KCCQ-os score after adjusting for 31 patient characteristics and 10 medications.
RESULTS Overall mean KCCQ-os scores were 64.2  24.0 but lower for women (29% of sample; 60.3  24.0 vs. 65.9
 24.0, respectively; p < 0.001), for blacks (60.5  25.0 vs. 64.9  23.0, respectively; p < 0.001), for Hispanics (59.1 
21.0 vs. 64.9  23.0, respectively; p < 0.001), and for those with the lowest income (<$25,000; mean: 57.1 vs. 63.1 to
74.7 for other income categories; p < 0.001). Fully adjusted KCCQ-os scores were 2.2 points lower for women (95%
confidence interval [CI]: 3.8 to 0.6; p ¼ 0.007), no different for blacks (p ¼ 0.74), 4.0 points lower for Hispanics
(95% CI: 6.6 to 1.3; p ¼ 0.003), and lowest in the poorest patients (4.7 points lower than those with the highest
income (95% CI: 0.1 to 9.2; p ¼ 0.045; p for trend ¼ 0.003).
CONCLUSIONS Among outpatients with HFrEF, women, blacks, Hispanics, and poorer patients had worse health
status, which remained significant for women, Hispanics, and poorer patients in fully adjusted analyses. This suggests an
opportunity to further optimize treatment to reduce these observed disparities. (J Am Coll Cardiol HF 2018;6:465–73)
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A primary goal of U.S. health care, asarticulated by the Department ofHealth and Human Services’ Healthy
People 2020 initiative, is to eradicate dispar-
ities in health status by sex, race/ethnicity,
and socioeconomic status (SES) (1). Prior
studies have demonstrated worse outcomes,
principally mortality and hospitalization
rates, in women, blacks, Hispanics, and pa-
tients with lower SES in the setting of heart
failure (2,3). However, a primary treatment
goal in heart failure is to optimize patients’
health status, including their symptoms, function,
and quality of life. To date, no studies have described
the health status of patients with heart failure and
reduced ejection fraction (HFrEF) in routine clinical
care. Given the many potential interventions avail-
able to improve the health status of patients with
HFrEF, identifying differences by sex, race/ethnicity,
or SES can highlight new opportunities to further
reduce these disparities in care.
To address this gap in knowledge, we compared
the health status of patients with HFrEF by sex,
race/ethnicity, and SES in the CHAMP-HF (Change
the Management of Patients with Heart Failure)
registry. CHAMP-HF is a large, prospective, multi-
center, observational study of outpatients with
HFrEF that captured patients’ health status by
using the short form of the Kansas City Cardiomy-
opathy Questionnaire-12 (KCCQ-12), a well-validated
measurement of patients’ symptoms, function, and
quality of life (4). Moreover, as payers increasingly
turn to patient-reported outcome measures, such
as the KCCQ-12 instrument, to quantify health care
quality, identifying populations of patients with
worse health status can form the foundation with
which to evaluate whether the use of such
performance measures can successfully reduce
health status disparities.
METHODS
STUDY DESIGN. CHAMP-HF, as previously described,
is a multicenter, observational registry developed
with the primary objective of capturing the outcomes
and real-world treatment patterns of patients with
HFrEF in the United States (5). Briefly, patients with
chronic HFrEF (left ventricular ejection fraction
[LVEF] #40%) being treated with at least 1 guideline-
recommended pharmacotherapy were consecutively
recruited from outpatient heart failure clinics. Sub-
jects were excluded if they were enrolled in a hospice
program or estimated to have a life expectancy of <1
year or had a history of heart transplantation, left
ventricular assist device implantation, or end-stage
kidney disease requiring hemodialysis. Eligible sites
were identified based upon the completion of a
feasibility survey, which provided investigators with
the opportunity to ensure broad geographic and
provider specialty representation. Study coordinators
at each site were responsible for identification and
enrollment of subjects during the course of a sched-
uled outpatient visit. CHAMP-HF was sponsored by
Novartis Pharmaceuticals Corp., and all participating
sites obtained local or central institutional review
board approval before subject enrollment as well as
informed consent from each participant. This study
leveraged baseline data from all patients enrolled
before March 6, 2017.
DATA COLLECTION. At the time of study subject
enrollment, site coordinators interviewed patients to
collect their self-identified race/ethnicity as well as
household income and health status and abstracted
their clinical history and medications. The primary
outcome for this analysis was disease-specific health
status, as assessed by the 12-item KCCQ-12. The
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KCCQ-12 is a valid, reliable, and sensitive 12-item HF-
specific patient-reported outcome form that quan-
tifies patients’ HF symptoms, physical and social
limitations, and quality of life (4,6). KCCQ-12 domains
can be summarized as an overall summary score that
ranges from 0 to 100, where higher scores reflect
better health status (fewer symptoms, less social
or physical limitations, and better quality of life).
A 5-point change in KCCQ-os is considered a clinically
meaningful difference in scores from both patients’
and providers’ perspectives (7,8). For descriptive
purposes, the KCCQ-os was divided (9) into poor
health status (score: <25), fair health status (score: 25
to 49), good health status (score: 50 to 74), and
excellent health status (score: 75 to 100). SES was
TABLE 1 Distribution of Patient Characteristics (N ¼ 3,494)









BMI, kg/m2 29.2 (25.5, 33.8)
Insurance status
Managed care 574 (16.4)
Private insurance 330 (9.4)
Medicare 2,038 (58.3)
Medicaid 317 (9.1)
Highest level of education
Less than high school 425 (12.2)
High school 1,187 (34.0)
Some college 1,094 (31.3)
4–yr college 440 (12.6)











Disability for medical reasons 877 (25.1)





Diabetes mellitus 1,426 (40.8)
Tobacco use/smoking 689 (19.7)
Atrial fibrillation 1,258 (36.0)











Continued in the next column
TABLE 1 Continued




Vital signs on enrollment
Systolic pressure, mm Hg 120 (110, 131)
Diastolic pressure, mm Hg 72 (64, 80)
Heart rate, beats/min 72 (66, 81)
Clinical measurements and laboratory results
LVEF, % 30 (23, 35)
NT-proBNP, pg/ml 2,013 (794, 5,490)
HbA1c, % 6.4 (5.8, 7.6)
Hemoglobin, g/dl 13.2 (11.8, 14.4)
Serum creatinine, mg/dl 1.1 (0.9, 1.4)
BUN, mg/dl 20.0 (16.0, 28.0)

















Number of medications 3.0 (2.0, 4.0)
Site characteristics
Physician specialty
Family practice 219 (6.3)
Internal medicine 266 (7.6)
HF specialist 718 (20.5)
Other cardiologist 2,086 (59.7)
Number of HF patients managed annually 1,200 (480, 3,000)
Values are median (Q1, Q3) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
ARNI ¼ angiotensin-receptor neprilysin inhibitor; BMI ¼ body mass index; BUN ¼
blood urea nitrogen; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive
pulmonary disease; CRT ¼ cardiac resynchronization therapy; eGFR ¼ estimated
glomerular filtration rate; HbA1c ¼ Hemoglobin A1c; HF ¼ heart failure; LVEF ¼
left ventricular ejection fraction; MRA ¼ mineralocorticoid antagonist; VT/VF ¼
ventricular tachycardia/ventricular fibrillation.
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characterized as total annual household income and
assessed by asking patients to use ordinal categories
of annual household income ranging from <$25,000
to >$150,000 per year.
STATISTICAL ANALYSIS. Distribution of continuous
KCCQ-os scores was described by mean  SD, median,
and 25th and 75th percentiles according to patient
characteristics that included sex, race/ethnicity, and
SES. We then used hierarchical linear regression
models, with site as a random effect to account for
clustering within sites, to identify patient character-
istics associated with patients’ health status. Our first
model incorporated patient sociodemographic and
clinical characteristics (model 1) with subsequent
adjustment for medical therapies (model 2) present
on enrollment. Backward selection was performed to
obtain the final models. Full models included all
variables shown in Table 1, except for laboratory re-
sults. Age, sex, and race/ethnicity were permanently
retained in the model. The maximum p value for
covariates to be retained in the model was set at 0.05.
The relationship between mean KCCQ-os score and
continuous variables are reported in units of 1 SD,
except for age, which was reported per 10 year in-
tervals. We tested the nonlinearity by using restricted
cubic splines. There was no evidence of nonlinearity
except for age, and therefore we used a linear spline
with a knot of 70 for age.
Rates of missing data for patient-level variables,
overall, were small (<8%), except for household in-
come, which was not reported by w24% of patients.
Missing values for continuous variables were imputed
using the sex/age/KCCQ group-specific median for
patient-level covariates. For categorical variables,
missing medical history variables were imputed to the
most common value. Missing procedures were
imputed as “no.” All estimates were reported using
95% confidence intervals (CIs) and an a ¼ 0.05 was
used to determine statistical significance. All analyses
were performed using SAS software version 9.4 (SAS
Institute, Cary, North Carolina). Analyses were per-
formed independently by Duke Clinical Research
Institute, and the lead author takes responsibility for
guiding data analysis and interpretation of the results.
RESULTS
A total of 3,552 patients were enrolled in the CHAMP-
HF registry before March 6, 2017. Of that sample, our
final analytic cohort consisted of 3,494 patients
across 140 sites after excluding patients with missing
FIGURE 1 Patient Exclusion Flowsheet






• 14 Patients with Unavailable
   KCCQ-os Data
• 10 Patients with Unavailable
   Demographic Data
TABLE 2 Distribution of KCCQ-os Score by Patient Subgroup
(N ¼ 3,494)
Age, yrs
<40 61.2  26.1 62.5 (40.1, 85.9)
40–64 61.9  25.0 63.9 (43.8, 83.3)
65–80 66.5  22.6 68.8 (50.0, 84.9)
>80 63.4  23.7 64.6 (44.8, 83.9)
Sex
Male 65.9  23.7 68.8 (47.9, 85.4)
Female 60.3  23.8 61.5 (43.8, 80.2)
Race
White 64.9  23.4 67.7 (47.9, 84.4)
Black 60.5  25.2 61.2 (41.7, 82.3)
Hispanic 59.1  21.0 58.3 (43.8, 75.0)
Insurance status
Managed care 68.2  24.1 71.9 (51.6, 88.5)
Private insurance 70.2  22.1 73.4 (55.7, 88.5)
Medicare 63.7  23.3 65.1 (46.4, 82.3)
Medicaid 56.1  24.6 54.2 (38.5, 76.6)
Highest level of education
Less than high school 58.3  23.2 57.3 (41.7, 76.6)
High school 62.5  24.0 64.6 (44.8, 81.8)
Some college 65.3  24.2 67.7 (46.9, 85.9)
4-yr college 67.8  22.9 71.1 (51.3, 87.5)
Graduate or other professional
degree
69.8  22.2 75.0 (53.4, 87.5)
Total household income
<$25,000 57.1  23.2 56.3 (40.6, 75.0)
$25,000–$49,999 63.1  24.2 66.1 (44.3, 83.3)
$50,000–$74,999 68.8  22.6 71.9 (53.1, 87.5)
$75,000–$99,999 69.9  22.6 75.0 (56.3, 87.5)
$100,000–$149,999 73.5  20.9 77.1 (58.9, 92.2)
$150,00 or More 74.6  21.0 83.3 (62.5, 89.6)
Employment status
Working full-time 74.6  21.9 80.2 (62.5, 91.7)
Working part-time 70.7  22.6 77.1 (57.3, 88.5)
Disability for medical reasons 52.9  23.7 52.1 (34.9, 70.8)
Not employed for other reasons 65.9  22.6 68.8 (49.0, 84.4)
Values are mean  SD and median (Q1, Q3).
KCCQ-os ¼ Kansas City Cardiomyopathy Questionnaire-overall summary score.
Khariton et al. J A C C : H E A R T F A I L U R E V O L . 6 , N O . 6 , 2 0 1 8
Health Status Disparities in Outpatients With HFrEF J U N E 2 0 1 8 : 4 6 5 – 7 3
468
KCCQ-os data (n ¼ 14), demographic data (n ¼ 10), and
those ineligible according to the study protocol
(n ¼ 34) (Figure 1). There was a broad range of patient-
reported KCCQ-os scores, encompassing poor (n ¼
228), fair (n ¼ 785), good (n ¼ 1,101), and excellent
(n ¼ 1,380) health status.
PATIENT CHARACTERISTICS AND HEALTH STATUS
ACROSS SUBGROUPS. Characteristics of the analytic
cohort are described in Tables 1 and 2, with information
on medication prescription by sex, race/ethnicity,
and SES provided in Online Tables 3a to 3d and New
York Heart Association (NYHA) functional classifica-
tion by sex, in Online Table 3e. Of the total sample, the
median agewas 68.0 (interquartile range [IQR]: 59.0 to
75.0) years, with more men than women (70.8% vs.
29.2%) and white (74.9%) than black (16.4%) or His-
panic (16.9%) patients. The total annual household
income was <$25,000 in 30.8% of participants,
whereas 2.7% reported incomes >$150,000. A signifi-
cant proportion had concomitant diagnoses of atrial
fibrillation, coronary artery disease, chronic obstruc-
tive lung disease, diabetesmellitus, and hypertension.
Finally, median documented LVEFwas 30% (IQR: 23%,
35%). Supporting the stability of this outpatient pop-
ulation, 87.6% of the cohort had no or only one hos-
pitalization within 12 months of enrollment in the
registry.
In regard to HF-related quality of life, the mean
KCCQ-os score was 64.2  23.9 in the overall sample.
Participants with good to excellent health status were
more often older ($65), male, and white. Online
Table S1 provides a detailed overview of patient
subgroup characteristics by ranges of KCCQ-os scores.
DIFFERENCES IN HEALTH STATUS BY SEX, RACE/
ETHNICITY, AND SES STATUS. Significant differences
in KCCQ-os scores by sex were observed in both un-
adjusted and adjusted analyses. In the unadjusted
model, women had worse KCCQ-os scores than men
(4.8 points; 95% CI: 6.5 to 3.1; p < 0.001). This
variability was modestly attenuated after adjusting
for other patient-level characteristics in model 1
(2.2 points; 95% CI: 3.7 to 0.6; p ¼ 0.007) (Online
Table S2), and remained statistically significant even
after adjusting for HF medications (2.2 points; 95%
CI: 3.8 to 0.6; p ¼ 0.007) (Table 3). Differences by
race/ethnicity were observed in unadjusted analyses,
with blacks (4.5 points; 95% CI: 6.7 to 2.2;
p < 0.001) and Hispanics (3.4 points; 95% CI: 6.1
to 0.6; p ¼ 0.016) having worse health status scores
than those of whites. For blacks, this difference was
fully explained after the addition of other patient
characteristics to model 1 (0.7 points; 95% CI: 2.9
to 1.4; p ¼ 0.52) (Online Table 2) and remained
insignificant after adjusting for medical therapies
(0.4 points; 95% CI: 2.5 to 1.8; p ¼ 0.736) (Table 3).
For Hispanics, clinically significant differences
remained after adjusting only for patient character-
istics in model 1 (3.4 points; 95% CI: 6.0 to 0.8;
p ¼ 0.011) (Online Table S2) and then medications
(4.0 points; 95% CI: 6.6 to 1.3; p ¼ 0.003) (Table 3)
in model 2.
Finally, large differences by household income
were observed between the highest- and lowest-paid
groups across unadjusted and adjusted analyses.
TABLE 3 Model 2: Unadjusted and Adjusted Association Between Patient Characteristics
and Medications at Enrollment with KCCQ-os (N ¼ 3,494)
Unadjusted Effect
(95% CI) p Value
Adjusted Effect
(95% CI) p Value
Age, 10-yr increments
#70 yrs 1.2 (0.5 to 1.8) <0.001 1.6 (0.6 to 2.6) 0.002
$70 yrs 0.2 (1.7 to 1.3) 0.765 5.5 (7.5 to 3.4) <0.001
Female (ref: male) 4.8 (6.5 to 3.1) <0.001 2.2 (3.8 to 0.6) 0.007
Race/ethnicity (ref: white)
Black 4.5 (6.7 to 2.2) <0.001 0.4 (2.5 to 1.8) 0.736
Other 0.1 (2.8 to 3.1) 0.930 3.1 (0.3 to 5.9) 0.031
Hispanic (ref: non-
Hispanic)
3.4 (6.1 to 0.6) 0.016 4.0 (6.6 to 1.3) 0.003
BMI to per 7.2 U 3.3 (4.0 to 2.5) <0.001 2.5 (3.3 to 1.8) <0.001
Total household income
(ref: <$25,000)
$25,000–$49,999 4.8 (2.6 to 7.1) <0.001 0.7 (1.4 to 2.8) 0.505
$50,000–$74,999 10.1 (7.5 to 12.7) <0.001 3.2 (0.7 to 5.7) 0.013
$75,000–$99,999 10.8 (7.4 to 14.2) <0.001 3.8 (0.6 to 7.0) 0.019
$100,000–$149,999 14.2 (10.6 to 17.8) <0.001 4.7 (1.3 to 8.1) 0.007
$150,000 or more 15.3 (10.4 to 20.1) <0.001 4.7 (0.1 to 9.2) 0.045
Prefer not to answer 0.9 (2.6 to 0.7) 0.267 1.8 (3.3 to 0.2) 0.029
Employment status
(ref: working full-time)
Working part-time 2.8 (6.1 to 0.6) 0.107 1.3 (4.5 to 1.9) 0.417
Disability for medical
reasons
20.4 (22.8 to 17.9) <0.001 14.3 (16.8 to 11.8) <0.001
Not employed for other
reasons
7.4 (9.6 to 5.2) <0.001 5.0 (7.4 to 2.5) <0.001
COPD 10.4 (12.1 to 8.7) <0.001 6.2 (7.7 to 4.6) <0.001
Chronic kidney disease 6.4 (8.3 to 4.4) <0.001 2.6 (4.4 to 0.8) 0.005
Depression 10.5 (12.3 to 8.7) <0.001 7.3 (9.0 to 5.7) <0.001
Atrial fibrillation 2.0 (3.6 to 0.4) 0.015 2.0 (3.5 to 0.5) 0.011
Coronary artery disease 0.9 (2.6 to 0.7) 0.267 1.8 (3.3 to 0.2) 0.029
Prior HF hospitalization in
past year (ref: 0)
1 5.2 (7.1 to 3.4) <0.001 2.8 (4.5 to 1.2) 0.001
$2 13.2 (15.6 to 10.7) <0.001 6.6 (8.9 to 4.3) <0.001
Pulse, per 12.5 beats/min 4.0 (4.8 to 3.2) <0.001 2.4 (3.1 to 1.7) <0.001
LVEF, per 8% 2.2 (1.5 to 3.0) <0.001 1.1 (0.4 to 1.9) 0.003
ARNI 1.2 (1.3 to 3.6) 0.3474 3.9 (1.5 to 6.4) 0.002
ACEi/ARB 3.6 (2.0 to 5.2) <0.001 3.6 (2.0 to 5.3) <0.001
Loop diuretic agent 8.2 (9.8 to 6.6) <0.001 4.4 (6.0 to 2.9) <0.001
Ivabradine 10.2 (17.2 to 3.2) 0.004 6.9 (13.2 to 0.6) 0.033
Inotrope 25.8 (37.9 to 13.6) <0.001 17.0 (27.9 to 6.1) 0.002
Abbreviations as in Table 1.
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In the unadjusted model, patients with the highest
level had a mean KCCQ-os score that was 15.3
points higher than those with the lowest income
(95% CI: 10.4 to 20.1; p < 0.001). This variability was
attenuated but still significantly different after
adjustment for other patient characteristics in model
1 (5.6 points; 95% CI: 1.0 to 10.2; p ¼ 0.02) (Online
Table 2) and persisted after adjusting for medical
therapies in model 2 (4.7 points; 95% CI: 0.1 to 9.2;
p ¼ 0.045) (Table 3). A test for trend across all
income levels was significant for both unadjusted
(p < 0.0001) and adjusted (p ¼ 0.003) models.
Both unadjusted and fully adjusted models for sex,
race/ethnicity, and SES are shown in Figure 2.
DISCUSSION
A primary goal for treating patients with HFrEF is to
minimize their symptoms and optimize their function
and quality of life (10). To accomplish this goal, cli-
nicians have a range of established and emerging
medical and device therapies (11–13), but whether
these are applied with similar success to optimize the
health status of patients with different sex, race/
ethnicity, and SES is unknown. In the present study,
we used data from CHAMP-HF to explore disparities
in health status by sex, race/ethnicity, and SES. We
found that, among a large population of patients with
HFrEF in outpatient clinical practice, women, blacks
and Hispanics, and lower-income patients had statis-
tically significantly worse HF-specific health status in
unadjusted analyses. Moreover, even after adjust-
ment for numerous patient and treatment factors, a
small but statistically significant worse KCCQ-os score
remained in women, Hispanics, and poorer patients.
CHAMP-HF is a contemporary registry that, for the
first time, captures the care and outcomes of patients
with HFrEF. Our findings describe significant dispar-
ities in the control of HF symptoms and optimization
of function and quality of life between women and
men, whites and Hispanics, and those with lower and
higher SES that warrant further efforts to achieve the
goals of equity in health care.
Our findings extend previous efforts to describe
disparities in the care of patients with HF by doc-
umenting differences in patients’ health status across
different sociodemographic groups. Thus, although
prior efforts have described sociodemographic dis-
parities in relation to cardiovascular mortality and
routine implementation of guideline-directed HFrEF
therapies, insights into health status disparities are
limited (14–16). For example, in regard to sex, our
results substantially extend several prior, smaller
studies suggesting better (17,18), worse (19–26), or
comparable (27) quality of life in women. Our analysis
describes health status in a larger, more
FIGURE 2 Unadjusted and Adjusted Mean KCCQ-os Score Disparities by Sex, Race/Ethnicity, and Socioeconomic Status












































Candidate variables considered for multivariate analyses were age, sex, race, BMI, insurance status, highest level of education, house income, employment status,
diabetes mellitus, CKD, COPD, depression, tobacco use/smoking, atrial fibrillation, CAD, hypertension, hyperlipidemia, ventricular tachycardia/fibrillation, CRT, number
of prior HF hospitalizations, systolic blood pressure, heart rate, LVEF, ACEi/ARB, beta-blocker, MRA, ARNI, loop diuretic agent, hydralazine, digoxin, ivabradine, ino-
trope, and number of HF medications. Variables included in multivariate analysis after backward selection were age, sex, race, BMI, house income, employment status,
CKD, COPD, depression, atrial fibrillation, number of prior HF hospitalizations, systolic blood pressure, heart rate, LVEF, ARNI, loop diuretic therapy, ivabradine, and
inotrope. Reference category for sex was male. Reference category for race/ethnicity was white. Reference category for total household income was <$25,000
(annually). ACEi/ARB ¼ angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ARNI ¼ angiotensin-receptor neprilysin inhibitor; BMI ¼ body mass
index; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; HF ¼
heart failure; LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid antagonist; other abbreviations as in Tables 1 and 2.
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contemporary stable HFrEF population. When inter-
preting our findings, we believe it is important to
focus upon the unadjusted, as opposed to only
adjusted, effect sizes. Although adjusting for con-
founders is very important in observational research
seeking to associate patient characteristics with out-
comes, in this case, we do not believe that there is a
biologically plausible reason why clinicians should be
less capable of controlling the symptoms and opti-
mizing the quality of life of women than that of men.
Finding a clinically important difference in KCCQ-os
scores in women from this large multicenter registry
suggests that we are not being as effective in opti-
mizing the health status of women with HFrEF
and that more research is needed to better under-
stand how to overcome these apparent sex-level
disparities. For example, prior studies associating
female sex with lower adherence to guideline-
directed HFrEF therapies may be one possible mech-
anism of health status inequality, although we did
account for differences in treatment in our analyses
(17). Whether, as others have suggested, these
differences are due to HF management knowledge,
perceived control, self-care confidence (28), or
competing demands between family responsibilities,
sex roles, and self-care (29–31) is unknown and
further studies are needed to identify how to deliver
care that is more equitable between men and women
with HFrEF (32).
Health disparities between whites and nonwhites
are well known, but racial variability in HF-specific
health status remains understudied (20,33,34). Our
findings parallel prior research that has shown poorer
perceived HF-related health (18) and steeper func-
tional decline (34) in blacks, although other studies
have failed to observe any racially driven associations
with health status during outpatient follow-up (35).
Although results of our fully adjusted model showed
no significant differences in health status between
whites and blacks, it remains noteworthy that unad-
justed health status differences between those groups
were statistically and clinically significant (w5 points
lower in blacks). This highlights an important reality
in the management of the HFrEF population, in that
African Americans have worse health status, whether
mediated by an underlying biological mechanism or
other sociodemographic patient characteristics, and
this should not be overlooked as part of routine
outpatient care. Multiple reasons for this variability
in health status have been postulated, including cul-
tural differences in what constitutes health and fac-
tors considered during self-evaluation of health
status (18), although there have been no reports
suggesting that these observed differences might not
be overcome with more aggressive therapy, an
important future research priority.
Our results concerning Hispanics are novel in that
they contradict earlier reports that Latin Americans
experienced comparable health status, on initial
evaluation, compared to other ethnic and racial groups
(33,36). As our study is descriptive (and the first to
report differences in the health status ofHispanics), we
cannot provide causal insights into these observations.
Finally, our findings are most indicative of sizeable
variability in HF-specific health status based on
financial income, with similar patterns having been
previously described (19,37–39). In our study, we
leveraged annual household income as a proxy for
SES, which coincides with definitions used previously
in published reports (18). Overall, our results can be
understood in the context of routine HF management,
where chronic illness is predictably disabling and
thereby forces patients to make significant lifestyle
changes that have an impact on overall quality of life.
By extension, an adequate financial income provides
an uninterrupted layer of insulation against barriers to
self-care created by inadequate resources (37).
One strategy that may help address these observed
disparities would be to routinely capture and report
patient-reported health status in clinical care, a
means of transparently and reproducibly document-
ing the symptoms, function, and quality of life of
patients with HF at each and every clinic visit. By
consistently capturing and reporting patients’ health
status, clinicians could readily identify those for
whom additional therapeutic strategies may be
needed to improve their management. Toward that
end, a new Medicare framework (40,41) has been
designed to reward providers for collecting patient-
reported outcomes measurements through the
Centers for Medicare and Medicaid Services Merit-
Based Payment System. However, although the
Centers for Medicare and Medicaid Services has
created a mechanism to encourage the collection of
patient-reported outcomes measurements, the means
of feasibly collecting, scoring, and reporting these
data at the time of a clinical visit will require further
work. Although it is possible that the routine collec-
tion of patients’ health status can reduce these health
status disparities, this will require further investiga-
tion after the implementation of patient-reported
outcome-based performance measures.
STUDY LIMITATIONS. Our findings must be inter-
preted in context of the following limitations. First,
although the CHAMP-HF registry is among the largest
cross-sectional assessments of the health status of
patients in routine clinical care, it was conducted in
voluntary participating sites committed to clinical
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research. Whether these findings are generalizable
throughout the United States is unknown, and our
estimates of health status disparities may not accu-
rately reflect the entire country. Second, our analysis
assessed health status at a single point in time
(enrollment), and further work will be needed to
describe the trajectories of patients’ health status
over time. Third, one-fourth of patients did not report
annual household income, and this was treated as a
separate category. Fourth, residual measured or un-
measured confounding might have influenced the
associations observed. Fifth, the use of multiple
comparisons might have influenced the statistical
significance and interpretation of final p values. Sixth
and finally, this initial, descriptive report was not
able to formally test mediators of observed difference
in health status across vulnerable groups nor define
practice patterns that might support intervention to
reduce these disparities.
CONCLUSIONS
In analyzing a unique, prospective observational
registry of patients with chronic HFrEF, we found
that women, blacks, and Hispanics and patients with
lower socioeconomic status had worse symptoms,
function, and health-related quality of life. After
multivariate adjustment, clinically significant dis-
parities remained across sex, race/ethnicity, and
socioeconomic groups. Our findings indicate that
previously reported disparities in survival and
hospitalization rates extend to patients’ health status
and underscore the need for novel strategies to
reduce health status disparities as well as future work
to better understand their complexity.
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